A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia.
about
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationComparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationProphylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationComparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationAlternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationDifferent doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationPhenotyping bleedingIndications for platelet transfusion in patients with thrombocytopeniaWhy has demand for platelet components increased? A reviewAlternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials.Dose of prophylactic platelet transfusions and prevention of hemorrhagePlatelet dose for prophylactic platelet transfusions.Platelet transfusions for patients with haematological malignancies: who needs them?Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system.Therapeutic options for immune-mediated thrombocytopenia.[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia.Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II studyThe observation of bleeding complications in haemato-oncological patients: stringent watching, relevant reporting.Intracranial haemorrhage in thrombocytopenic haematology patients--a nested case-control study: the InCiTe study protocolProspective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- the ATHENA study.Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation.Transfusion support in patients with dengue fever.A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial.Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot studyExtended Small-Dose Platelet Transfusions in Multitransfused Hemato-Oncological Patients: A Single-Center Experience.Toward a patient-based paradigm for blood transfusion.Bias in transfusion research: from study design to result reporting.The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions.Clinical effectiveness and comparative hospital costs of different platelet dose strategies.Platelet transfusion: a systematic review of the clinical evidence.Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations.The association between platelet transfusion and idiopathic pneumonia syndrome is unaffected by platelet product type.Platelet dysfunction contributes to bleeding complications in patients with probable leptospirosis.Time to rethink clinically important outcomes in platelet transfusion trials.Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets.The effect of various platelet dosing strategies on transfusion costs.
P2860
Q24186359-41ADCAC4-5BC6-4083-BC61-9B66C73777EBQ24186913-4B709DB0-C755-481E-AD4C-8301F70BA3B3Q24187751-8233781D-8950-45B8-B5B2-FDC2FEA08DCAQ24197779-99C6AC25-24DA-40CB-9568-A5E2EB773AE6Q24198288-A6E20D2C-1D19-4283-AE6F-A833564F6BF5Q24198774-29A0EF73-D152-4F01-B12A-560E39E740F1Q24198795-78801712-75D2-4334-AE04-D21F2D42BF7CQ24198832-0E334314-717E-47DD-908A-D69E438A05DEQ26830732-1D3A2FBA-D663-48F9-B27C-F5085E3E2AB7Q27023734-AE6BAD1D-8BE8-4343-82AB-A5E8B22205F5Q28249969-B34DC6F4-E077-406E-A18B-D43F498AF11BQ30248355-2CFB4BA3-2671-4CAB-80BE-01C623794EF4Q30248755-DA591035-5619-44AB-A6F8-588057AC75D6Q30496886-87722A2D-A1A4-40C4-AB73-B0586F5B5C9DQ33392855-4E0BD6D4-CCD4-478C-BC0C-71433C6D2E22Q33395509-3FFE5CBB-5BC1-4DEB-9117-5986B873BA53Q33397396-77661AF6-DBB5-4676-9FE7-C5503548C1C7Q33399601-514EC6AC-456F-4414-A111-299110E2A381Q33400018-A16BC91D-1D77-421E-B89E-3C069AE73F14Q33400629-51F587CA-4D89-4E6D-8A9A-0D25E0C19AFFQ33401660-85572F7A-8032-47D1-809B-3CFC0D32F098Q33403659-93F057C4-BB5D-40E2-A1A1-F9084177D1DAQ33413225-D045342A-F89C-48DC-A7F8-EE12CF8E58F9Q33415057-5B8E71E3-C5CD-44DA-99A3-71069D08DD51Q33417080-4E497C99-C525-4BFA-9D82-F462F9E01B6EQ33418078-3B22DAA2-B50C-46FE-805F-2E9E6BCB5493Q33429565-C8997EFC-7E7B-4166-82FC-E525A34A13A8Q33436425-49D8AFA5-7250-4A75-89A5-1F32DE3E8FD1Q33441106-08151D43-67F1-4F3A-9786-611569AD61C3Q37568315-09F6EA54-34DB-4ACE-AE4C-62E57A22ED2DQ37839134-45E43552-2337-4924-8C9C-958F26AF65DDQ38073018-E7EE14DB-405E-4CF7-9262-2F833FA6449DQ38235211-72A84E41-9EC3-4ABD-A840-F8D6247729EAQ38267183-7A7D4946-9AF3-474B-A3B5-07651E29A8B1Q39521376-2C38BBF5-DD6B-405F-9106-967839CBDC69Q41264625-7442FDA8-0724-41E1-B589-F7BBCEE59559Q41995651-EFD5FF4A-076C-4343-A719-4C71ECC2A0B6Q44398526-CCFAA0A6-19D2-4E71-933E-6B5B0A434C7AQ46115563-327EEC04-ABA6-4657-8E18-C68C49C2DBE0Q46615401-068870E5-9B74-44E7-BF9F-60A7E421EB3A
P2860
A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
A randomized controlled trial ...... atients with thrombocytopenia.
@ast
A randomized controlled trial ...... atients with thrombocytopenia.
@en
type
label
A randomized controlled trial ...... atients with thrombocytopenia.
@ast
A randomized controlled trial ...... atients with thrombocytopenia.
@en
prefLabel
A randomized controlled trial ...... atients with thrombocytopenia.
@ast
A randomized controlled trial ...... atients with thrombocytopenia.
@en
P2093
P1433
P1476
A randomized controlled trial ...... atients with thrombocytopenia.
@en
P2093
Alan Tinmouth
C Tom Kouroukis
Ellen Klapper
James P AuBuchon
Joseph M Brandwein
Ker-Ai Lee
Nancy M Heddle
Rebecca L Barty
Richard J Cook
SToP Study Investigators of the BEST Collaborative
P304
P356
10.1182/BLOOD-2008-09-178236
P407
P577
2008-12-24T00:00:00Z